Advertisement

Apixaban Gains Indication for DVT Prophylaxis After Knee and Hip Replacement — Physician’s First Watch

Medical News |
March 17, 2014

Apixaban Gains Indication for DVT Prophylaxis After Knee and Hip Replacement

By Larry Husten

The FDA has approved the anticoagulant apixaban (Eliquis) for the prophylaxis of deep vein thrombosis (DVT) in patients who have undergone hip or knee replacement surgery. The new indication joins the previously approved indication of stroke prevention in patients who have nonvalvular atrial fibrillation.

The DVT indication is based on results of the ADVANCE clinical trial program in which apixaban was compared with enoxaparin in more than 11,000 patients (see background links below).

Adapted from CardioExchange

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement